Cornerstone Planning Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cornerstone Planning Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$586	–	1878
2026 Q1	$586	Buy	+11	New	+$641	﹤0.01%	1601
2025 Q4	–	Sell	-1	Closed	-$2	–	1724
2025 Q3	$2	Buy	+1	New	+$57	﹤0.01%	1693
2025 Q2	–	Sell	-33	Closed	-$2.04K	–	1547
2025 Q1	$2.04K	Sell	33 -2	-6%	-$135	﹤0.01%	978
2024 Q4	$2.16K	Buy	35 +26	+289%	+$1.74K	﹤0.01%	778
2024 Q3	$629	Hold	9	–	–	﹤0.01%	1039
2024 Q2	$725	Buy	+9	New	+$749	﹤0.01%	1016
2024 Q1	–	Sell	-100	Closed	-$9.64K	–	1115
2023 Q4	$9.64K	Hold	100	–	–	﹤0.01%	436
2023 Q3	$8.85K	Sell	100 -6	-6%	-$534	﹤0.01%	451
2023 Q2	$9.19K	Buy	+106	New	+$9.97K	﹤0.01%	699

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Cornerstone Planning Group's BMRN Position: Q2 2026 in Review

Cornerstone Planning Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 11 shares — an estimated $586 sold.

Cornerstone Planning Group first reported a position in BMRN in Q2 2023 and held it in 9 quarters. The position peaked at $9.64K in Q4 2023. 261 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Cornerstone Planning Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cornerstone Planning Group sold 11 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $586.
Cornerstone Planning Group first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 9 quarters.
Cornerstone Planning Group's BioMarin Pharmaceuticals position peaked at $9.64K in Q4 2023.
261 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.